These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 15184018)

  • 1. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temperature-dependent intermediates in HIV-1 envelope glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal helical regions of HIV-1 gp41.
    Gallo SA; Clore GM; Louis JM; Bewley CA; Blumenthal R
    Biochemistry; 2004 Jun; 43(25):8230-3. PubMed ID: 15209519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides.
    Malashkevich VN; Chan DC; Chutkowski CT; Kim PS
    Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9134-9. PubMed ID: 9689046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
    Korazim O; Sackett K; Shai Y
    J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
    Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
    Soonthornsata B; Tian YS; Utachee P; Sapsutthipas S; Isarangkura-na-Ayuthaya P; Auwanit W; Takagi T; Ikuta K; Sawanpanyalert P; Kawashita N; Kameoka M
    Virology; 2010 Sep; 405(1):157-64. PubMed ID: 20580393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calmodulin binding properties of peptide analogues and fragments of the calmodulin-binding domain of simian immunodeficiency virus transmembrane glycoprotein 41.
    Yuan T; Tencza S; Mietzner TA; Montelaro RC; Vogel HJ
    Biopolymers; 2001 Jan; 58(1):50-62. PubMed ID: 11072229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimerized CHR-derived peptides as HIV-1 fusion inhibitors.
    Nomura W; Hashimoto C; Suzuki T; Ohashi N; Fujino M; Murakami T; Yamamoto N; Tamamura H
    Bioorg Med Chem; 2013 Aug; 21(15):4452-8. PubMed ID: 23800723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
    Liu S; Boyer-Chatenet L; Lu H; Jiang S
    J Biomol Screen; 2003 Dec; 8(6):685-93. PubMed ID: 14711394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
    Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
    J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
    Dwyer JJ; Hasan A; Wilson KL; White JM; Matthews TJ; Delmedico MK
    Biochemistry; 2003 May; 42(17):4945-53. PubMed ID: 12718536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34.
    Wang LX; Song H; Liu S; Lu H; Jiang S; Ni J; Li H
    Chembiochem; 2005 Jun; 6(6):1068-74. PubMed ID: 15883971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies.
    Mzoughi O; Gaston F; Granados GC; Lakhdar-Ghazal F; Giralt E; Bahraoui E
    ChemMedChem; 2010 Nov; 5(11):1907-18. PubMed ID: 20922745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.
    Desmezieres E; Gupta N; Vassell R; He Y; Peden K; Sirota L; Yang Z; Wingfield P; Weiss CD
    J Virol; 2005 Apr; 79(8):4774-81. PubMed ID: 15795263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipopeptides derived from HIV and SIV mimicking the prehairpin intermediate of gp41 on solid supported lipid bilayers.
    Schuy S; Schäfer E; Yoder NC; Kumar K; Vogel R; Janshoff A
    J Struct Biol; 2009 Oct; 168(1):125-36. PubMed ID: 19406246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A salt bridge between an N-terminal coiled coil of gp41 and an antiviral agent targeted to the gp41 core is important for anti-HIV-1 activity.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Apr; 270(1):153-7. PubMed ID: 10733920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
    Dimitrov AS; Rawat SS; Jiang S; Blumenthal R
    Biochemistry; 2003 Dec; 42(48):14150-8. PubMed ID: 14640682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
    Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
    Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.